S-equol in Women With Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if S-equol, an ER-beta agonist, is
effective in decreasing the proliferation rate of triple negative breast cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio